Institut Català d'Oncologia IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
Breast. 2021 Aug;58:160-169. doi: 10.1016/j.breast.2021.05.008. Epub 2021 May 25.
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR) and human epidermal growth factor receptor 2-negative (HER2) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
CDK4/6 抑制剂（CDK4/6i）在治疗晚期激素受体阳性（HR）和人表皮生长因子受体 2 阴性（HER2）乳腺癌（BC）方面已被证明是一种成功的策略，这引起了人们对其在早期 luminal BC 治疗中可能发挥作用的强烈兴趣。在这篇综述中，我们收集了关于 CDK4/6i 在新辅助和辅助治疗早期 BC 中的应用的最相关和最新信息。具体来说，我们评估了最近公布的大型 III 期辅助试验的结果，这些试验得出了明显不同的结果。我们还研究了生物标志物作为 CDI4/6i 反应预测因素的相关性，以及放疗和 CDK4/6i 的联合应用，并对我们迄今所拥有的证据以及这些药物在早期 BC 治疗中的作用的未来方向进行了批判性讨论。
